论文部分内容阅读
单用口服降糖药血糖控制不佳的2型糖尿病患者分别加用甘精胰岛素或中性鱼精蛋白锌胰岛素(NPH)联合治疗3个月,然后停止胰岛素治疗,恢复原口服治疗方案,共观察6个月。结果甘精胰岛素组的HbAIC和餐后血糖低于NPH组[治疗3个月(6．1±0．5)％vs(6．9±0．8)％和(7．2±2．1)mmol／L vs(9．3±3．1)mmol／L,治疗6个月(6．6±0．7)％vs(7．4±1．1)％和(8．8±2．8)mmol／Lvs(10．3±3．1) mmoL／L,P<0．01或P<0．05],两指标的下降值甘精胰岛素组大于NPH组[治疗3个月(4．0±0．7)％vs (3．7±0．6)％和(7．1 4-2．0)mmol／Lvs(5．9±1．8)mmol／L,治疗6个月(3．5±0．5)％vs(3．2±0．3)％和(5．5±1．4)mmol／Lvs(4．9±1．3)mmol／L,P<0．01或P<0．05],提示使用甘精胰岛素可以在不增加不良反应的情况下比NPH更加全面而有效地控制血糖。
Patients with type 2 diabetes mellitus who were not controlled by oral hypoglycemic agents alone were treated with insulin glargine or NPH for 3 months and then stopped insulin treatment to restore the original oral treatment Observe for 6 months. Results HbAIC and postprandial blood glucose in insulin glargine group were lower than those in NPH group [6.1 ± 0.5% vs 6.9 ± 0.8% vs 7.2 ± 2.1 ) vs (9.3 ± 3.1) mmol / L for 6 months (6.6 ± 0.7)% vs (7.4 ± 1.1)% and (8.8 ± 2) .8) mmol / Lvs (10.3 ± 3.1) mmoL / L, P <0.01 or P <0.05]. The decline of both indexes was higher in insulin glargine group than in NPH group [3 months 4.0 ± 0.7% vs 3.7 ± 0.6% and 7.14-2.0 mmol / L vs 5.9 ± 1.8 mmol / L, respectively (3.5 ± 0.5)% vs (3.2 ± 0.3)% and (5.5 ± 1.4) mmol / L vs (4.9 ± 1.3) mmol / L, P < 0.01 or P <0.05], suggesting that glargine can be used to control blood glucose more completely and effectively than NPH without increasing adverse reactions.